AAAAAA
Results:
1-9
|
Results: 9
Authors:
NICOLAISEN EM
Citation: Em. Nicolaisen, ANTIGENICITY OF ACTIVATED RECOMBINANT FACTOR-VII FOLLOWED THROUGH 9 YEARS OF CLINICAL-EXPERIENCE, Blood coagulation & fibrinolysis, 9, 1998, pp. 119-123
Authors:
NICOLAISEN EM
KRISTENSEN H
KRISTENSEN AT
EZBAN M
VERLAND S
CHRISTENSEN E
HEDNER U
Citation: Em. Nicolaisen et al., ANTIGENICITY OF CHLOROMETHYL-KETONE-INACTIVATED RECOMBINANT FVIIA (CMK-RFVIIA), EVALUATED IN AN EXPERIMENTAL HUMAN FVII-IMMUNE-TOLERANT MODEL, Thrombosis and haemostasis, 1997, pp. 2804-2804
Authors:
NICOLAISEN EM
HANSEN LL
POULSEN F
GLAZER S
HEDNER U
Citation: Em. Nicolaisen et al., IMMUNOLOGICAL ASPECTS OF RECOMBINANT FACTOR VIIA (RFVIIA) IN CLINICALUSE, Thrombosis and haemostasis, 76(2), 1996, pp. 200-204
Authors:
NICOLAISEN EM
Citation: Em. Nicolaisen, LONG-TERM FOLLOW-UP WITH REGARD TO POTENTIAL IMMUNOGENICITY - CLINICAL-EXPERIENCE WITH NOVOSEVEN(R) (RECOMBINANT FACTOR VIIA), Haemostasis, 26, 1996, pp. 98-101
Authors:
BECH RM
NICOLAISEN EM
ANDERSEN PM
GLAZER S
HEDNER U
Citation: Rm. Bech et al., RECOMBINANT FACTOR-VIIA FOR THE TREATMENT OF CONGENITAL FACTOR-VII DEFICIENT PATIENTS, Thrombosis and haemostasis, 73(6), 1995, pp. 983-983
Authors:
PERSSON E
EZBAN M
NICOLAISEN EM
ERHARDTSEN E
HEDNER U
Citation: E. Persson et al., EFFECTS OF ACENOCOUMAROL TREATMENT ON HUMAN PLASMA FACTOR-VII, Thrombosis and haemostasis, 73(6), 1995, pp. 1404-1404
Authors:
MOLLERUP I
BAYNE S
HALKJAER E
JORGENSEN T
MANDRUP G
NICOLAISEN EM
THIM L
Citation: I. Mollerup et al., THE USE OF RP-HPLC FOR MEASURING ACTIVATION AND CLEAVAGE OF RFVIIA DURING PURIFICATION, Biotechnology and bioengineering, 48(5), 1995, pp. 501-505
Authors:
NICOLAISEN EM
Citation: Em. Nicolaisen, CATHEPSIN G-MEDIATED CLEAVAGE OF FVIIA, Thrombosis and haemostasis, 71(4), 1994, pp. 530-530
Authors:
NICOLAISEN EM
HANSEN LL
POULSEN F
SELMER J
Citation: Em. Nicolaisen et al., ANTIGENICITY OF RECOMBINANT FVIIA, PRECLINICAL AND CLINICAL-STUDIES, Thrombosis and haemostasis, 69(6), 1993, pp. 851-851
Risultati:
1-9
|